BioVentrix names Carl Byrnes CFO

By AI, Created 9:57 AM UTC, May 20, 2026, /AGP/ – BioVentrix appointed finance veteran Carl Byrnes as chief financial officer on May 12, 2026, adding capital markets and investor relations experience as the medical device company advances its heart-failure program. The move comes as BioVentrix works through a pivotal U.S. study of its Revivent System.

Why it matters: - Carl Byrnes joins BioVentrix at a point when the company is linking financing decisions to clinical milestones. - The CFO hire adds experience in capital strategy, investor engagement and operating discipline as BioVentrix advances a pivotal study for its heart-failure device. - Stronger financial leadership can matter for a development-stage medtech company that must fund trials, manage timelines and position itself for future commercialization.

What happened: - BioVentrix named Carl Byrnes chief financial officer on May 12, 2026. - Byrnes will lead capital strategy and financing initiatives tied to key clinical milestones. - Byrnes will also strengthen financial planning and operating discipline while supporting investor engagement. - David Richmond, chair of the board, said Byrnes brings deep financial management and investor relations expertise to BioVentrix.

The details: - Byrnes has more than 25 years of finance experience across capital markets, corporate finance and operational leadership. - His background is primarily in biotechnology, pharmaceuticals and medical devices. - Most recently, Byrnes was managing director and senior research analyst for healthcare at Northland Capital Markets. - At Northland, Byrnes advised institutional investors on investment strategy, valuation and market dynamics. - Byrnes also worked with corporate leadership teams on investor positioning and market communications. - Before Northland, Byrnes was chief executive officer and chief financial officer of SCS Refrigerated Services. - At SCS Refrigerated Services, Byrnes led the recapitalization and sale of the company to Lineage Logistics, backed by Bay Grove Capital. - Byrnes said he is excited to join BioVentrix during an important stage of development and to support the company’s capital strategy as it executes its pivotal study.

Between the lines: - The hire suggests BioVentrix is preparing for a more capital-intensive phase as the RELIVE trial advances. - Byrnes’ background in investor communications points to a focus on market credibility as well as internal finance. - BioVentrix is signaling that execution on clinical and corporate milestones will shape financing needs and timing.

What’s next: - BioVentrix will continue its RELIVE Study, the company’s pivotal U.S. clinical trial. - Byrnes is expected to support the next phase of clinical and corporate execution. - Future financing and investor updates will likely track trial progress and other clinical milestones.

The bottom line: - BioVentrix is adding a finance executive with capital markets depth as it pushes a heart-failure device through pivotal testing.